scholarly journals A trend of dropping anti‐SARS‐CoV‐2 plaque reduction neutralization test titers over time in Canadian convalescent plasma donors

Transfusion ◽  
2021 ◽  
Author(s):  
Steven J. Drews ◽  
Dana V. Devine ◽  
Janet McManus ◽  
Emelissa Mendoza ◽  
Kathy Manguiat ◽  
...  
Keyword(s):  
Neutralization Test ◽  
Plaque Reduction Neutralization Test ◽  
Over Time

scholarly journals Comparison of JEV neutralization assay using pseudotyped JEV with the conventional plaque-reduction neutralization test

2014 ◽  
Vol 52 (5) ◽  
pp. 435-440 ◽  
Author(s):  
Hee-Jung Lee ◽  
Kyung-Il Min ◽  
Ki Hoon Park ◽  
Hyo Jung Choi ◽  
Min-Kyoung Kim ◽  
...  
Keyword(s):  
Neutralization Test ◽  
Neutralization Assay ◽  
Plaque Reduction Neutralization Test

scholarly journals Varicella-zoster plaque assay and plaque reduction neutralization test by the immunoperoxidase technique

1976 ◽  
Vol 4 (5) ◽  
pp. 437-442
Author(s):  
G Gerna ◽  
R W Chambers
Keyword(s):  
Neutralization Test ◽  
Plaque Assay ◽  
Neutralizing Antibody ◽  
Immunoperoxidase Technique ◽  
Serum Samples ◽  
Plaque Reduction Neutralization Test ◽  
Varicella Zoster ◽  
Convalescent Phase ◽  
Antibody Titers ◽  
Indirect Immunoperoxidase

A new plaque assay for the quantitation of varicella-zoster virus and a plaque reduction neutralization test for the determination of neutralizing antibody titer have been developed using the indirect immunoperoxidase technique. As compared with the classical plaque assay using a solid overlay, the test gives earlier results since plaque counting can be performed on day 3 after the inoculation of cell cultures. In six patients with zoster infection, neutralizing antibody titers ranged from 1:20 to 1:40 before the onset of infection and reached high levels (1:320 to 1:5,120) during the convalescent phase of the disease. Complement-fixing (CF) titers were all negative (less than 1:8) in prezoster serum samples from the same patients and ranged from 1:128 to 1:2,048 in the convalescent-phase sera. In the two cases in which late serum samples were available, neutralizing antibody titers matched the preillness levels, whereas CF titers dropped to undetectable levels. Neither neutralizing nor CF antibody was detected in two sera from individuals with no history of varicella-zoster infection. No differences in virus titers or neutralizing antibody titers were observed between the immunoperoxidase and the classical plaque assays. The appropriate characterization of reagent specificity is required before routine application of the test.

scholarly journals Assessment of Mumps Virus-Specific Antibodies: Comparison of Plaque Reduction Neutralization Test and Enzyme-Linked Immunosorbent Assay Estimates

2019 ◽  
Vol 220 (9) ◽  
pp. 1462-1468 ◽  
Author(s):  
Stéphanie Ravault ◽  
Damien Friel ◽  
Emmanuel Di Paolo ◽  
Adrian Caplanusi ◽  
Paul Gillard ◽  
...  
Keyword(s):  
Antibody Response ◽  
Immunosorbent Assay ◽  
Neutralizing Antibodies ◽  
Neutralization Test ◽  
Pearson Correlation ◽  
Mumps Virus ◽  
Enzyme Linked Immunosorbent Assay ◽  
Serological Response ◽  
Moderate Correlation ◽  
Plaque Reduction Neutralization Test

Abstract Background The plaque reduction neutralization test (PRNT), which measures a subset of immunoglobulin antibodies (functional neutralizing antibodies), and the enzyme-linked immunosorbent assay (ELISA), which measures total immunoglobulin (neutralizing and nonneutralizing antibodies), characterize different aspects of the anti–mumps virus antibody response after vaccination. Methods Data from a recent phase 3 clinical trial (NCT01681992) of 2 measles-mumps-rubella vaccines were used to compare anti-mumps antibody responses measured using an unenhanced PRNT (GSK; seropositivity cutoff and threshold, 2.5 and 4 times the 50% end-point dilution, respectively) with those estimated using an ELISA (thresholds, 5 and 10 ELISA units/mL, respectively). Results Of 3990 initially seronegative samples, 3284 (82.3%) were seropositive after vaccination for anti-mumps antibodies in both assays. The Pearson correlation coefficient for double-positive samples was 0.57, indicative of a moderate correlation. Receiver operating characteristic curve analysis showed that an ELISA threshold of 51.7 ELISA units/mL best corresponded to the PRNT seroresponse threshold. There was no obvious vaccine brand effect on the correlation between assays. Conclusions The moderate correlation between the anti-mumps antibody measurements obtained with PRNT and ELISA reflects different aspects of the serological response. In the absence of a well-defined protective serological threshold, PRNT provides complementary information on the antibody response, whereas ELISA remains a critically useful measurement of vaccine immunogenicity.

scholarly journals Serum Neutralization Assay Can Efficiently Replace Plaque Reduction Neutralization Test for Detection and Quantitation of West Nile Virus Antibodies in Human and Animal Serum Samples

2014 ◽  
Vol 21 (10) ◽  
pp. 1460-1462 ◽  
Author(s):  
Annapia Di Gennaro ◽  
Alessio Lorusso ◽  
Claudia Casaccia ◽  
Annamaria Conte ◽  
Federica Monaco ◽  
...  
Keyword(s):  
West Nile Virus ◽  
Neutralization Test ◽  
Neutralization Assay ◽  
Serum Samples ◽  
West Nile ◽  
Plaque Reduction Neutralization Test ◽  
Serum Neutralization ◽  
Human Sera

ABSTRACTA serum neutralization assay (SN) was compared with the official plaque reduction neutralization test for the quantitation of West Nile virus antibodies. A total of 1,348 samples from equid sera and 38 from human sera were tested by these two methods. Statistically significant differences were not observed, thus supporting the use of SN for routine purposes.

scholarly journals Persistence of Antibodies to West Nile Virus in Naturally Infected Rock Pigeons (Columba livia)

2005 ◽  
Vol 12 (5) ◽  
pp. 665-667 ◽  
Author(s):  
Samantha E. J. Gibbs ◽  
Douglas M. Hoffman ◽  
Lillian M. Stark ◽  
Nicole L. Marlenee ◽  
Bradley J. Blitvich ◽  
...  
Keyword(s):  
West Nile Virus ◽  
Immunosorbent Assay ◽  
Neutralization Test ◽  
Columba Livia ◽  
Maternal Antibodies ◽  
Enzyme Linked Immunosorbent Assay ◽  
West Nile ◽  
Entire Study ◽  
Plaque Reduction Neutralization Test ◽  
Antibody Persistence

ABSTRACT Wild caught rock pigeons (Columba livia) with antibodies to West Nile virus were monitored for 15 months to determine antibody persistence and compare results of three serologic techniques. Antibodies persisted for the entire study as detected by epitope-blocking enzyme-linked immunosorbent assay and plaque reduction neutralization test. Maternal antibodies in squabs derived from seropositive birds persisted for an average of 27 days.

scholarly journals Temporal Analysis of COVID-19 Convalescent Plasma Donations Reveals Significant Decrease in Neutralizing Capacity Over Time

2020 ◽  
Author(s):  
Roxie C. Girardin ◽  
Alan P. Dupuis ◽  
Anne F. Payne ◽  
Timothy J. Sullivan ◽  
Donna Strauss ◽  
...  
Keyword(s):  
Gold Standard ◽  
Infectious Virus ◽  
Neutralization Test ◽  
Temporal Analysis ◽  
Therapy Efficacy ◽  
Neutralizing Capacity ◽  
Seriously Ill Patients ◽  
The Relationship ◽  
Seriously Ill ◽  
Over Time

AbstractCOVID-19 convalescent plasma (CCP) received approval for use under an Emergency Use Authorization by the FDA for treatment of seriously ill patients. Use of CCP units with a signal-to-cutoff ratio of ≥12 using the Ortho VITROS SARS-CoV-2 IgG test (OVSARS2IgG) is authorized. Little is known about the relationship between this ratio and the neutralizing capacity of plasma/sera against genuine SARS-CoV-2 virus. We measured the neutralizing capacity of 981 samples from 196 CCP donors 7-119 days post initial donation (DPID). Neutralizing capacity was assessed for 50% (PRNT50) and 90% (PRNT90) reduction of infectious virus using the gold standard plaque reduction neutralization test (PRNT). Importantly, while 32.7%/79.5% (PRNT90/PRNT50) of donations met the FDA minimum titer of 1:80 initially, only 14.0%/48.8% (PRNT90/PRNT50) met this cut-off ≥85 DPID. A subset of 91 donations were evaluated using the OVSARS2IgG and compared to PRNT titers for diagnostic accuracy. The correlation of OVSARS2IgG results to neutralizing capacity allowed extrapolation to CCP therapy efficacy results. CCP with OVSARS2IgG ratios in the therapeutically beneficial group had neutralizing titers of ≥1:640 (PRNT50) and/or ≥1:80 (PRNT90). This information provides a new basis for refining the recommended properties of CCP that is used to treat severe COVID-19.

Sign in / Sign up

Export Citation Format

Share Document